Abstract
TQ-B3101 is a novel small molecule receptor tyrosine kinase inhibitor, which targets to ALK, ROS1 and MET. Preclinical studies showed that it had a good tumor inhibition activity and duration. This study aims to evaluate the efficacy and safety of TQ-B3101 monotherapy in the first-line treatment in patients with ROS1-positive non-small cell lung cancer (NSCLC).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
